Elsevier

Journal of Cystic Fibrosis

Volume 13, Issue 5, September 2014, Pages 557-563
Journal of Cystic Fibrosis

Original Article
An observational study of matrix metalloproteinase (MMP)-9 in cystic fibrosis

https://doi.org/10.1016/j.jcf.2014.01.010Get rights and content
Under an Elsevier user license
open archive

Abstract

Background

In cystic fibrosis (CF), cross-sectional studies have reported sputum matrix metalloproteinase (MMP)-9 to be elevated and negatively correlated with FEV1. This longitudinal study examined the association between MMP-9 and tissue inhibitors of metalloproteinases (TIMPs) to prognostic parameters in CF.

Method

A cross-sectional survey of CF and control subjects; CF patients were followed up for a median of 49 months. MMP-9 and TIMP-1 and TIMP-2 were quantified in sputum and plasma.

Results

Seventy-three patients with CF, median age 22 years, and 40 controls were recruited. Fifty-three of these CF patients were followed up. Prospectively, in CF subjects, plasma MMP-9 activity was adversely associated with FEV1 (β − 1.15 (95% CI − 2.10, − 0.20), p = 0.019) and rate of FEV1 decline, and plasma TIMP-1 was adversely associated with mortality: hazard ratio 3.66 (1.91–7.04), p < 0.001.

Conclusions

These associations further justify investigation of MMP-9 and TIMP-1 as biomarkers for short- to medium-term FEV1 decline and mortality in patients with CF.

Keywords

Cystic fibrosis
FEV1
MMP-9
TIMP-1
Mortality

Cited by (0)